These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 6244418)

  • 1. delta 9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy.
    Lucas VS; Laszlo J
    JAMA; 1980 Mar; 243(12):1241-3. PubMed ID: 6244418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
    Citron ML; Herman TS; Vreeland F; Krasnow SH; Fossieck BE; Harwood S; Franklin R; Cohen MH
    Cancer Treat Rep; 1985 Jan; 69(1):109-12. PubMed ID: 2981616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. delta 9-tetrahydrocannabinol in clinical oncology.
    Poster DS; Penta JS; Bruno S; Macdonald JS
    JAMA; 1981 May 22-29; 245(20):2047-51. PubMed ID: 6262541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine.
    Orr LE; McKernan JF
    J Clin Pharmacol; 1981; 21(S1):76S-80S. PubMed ID: 6271846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapy.
    Dow GJ; Meyers FH
    J Clin Pharmacol; 1981; 21(S1):128S-132S. PubMed ID: 6271818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. delta 9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study.
    Sweet DL; Miller NJ; Weddington W; Senay E; Sushelsky L
    J Clin Pharmacol; 1981; 21(S1):70S-75S. PubMed ID: 6271845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stress inoculation training in the control of THC toxicities.
    Roffman RA
    Int J Addict; 1986 Aug; 21(8):883-96. PubMed ID: 3021638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting.
    Lane M; Vogel CL; Ferguson J; Krasnow S; Saiers JL; Hamm J; Salva K; Wiernik PH; Holroyde CP; Hammill S
    J Pain Symptom Manage; 1991 Aug; 6(6):352-9. PubMed ID: 1652611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. delta 9-Tetrahydrocannabinol and therapeutic research legislation for cancer patients.
    Treffert DA; Joranson DE
    JAMA; 1983 Mar; 249(11):1469-72. PubMed ID: 6298477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic issues of marijuana and THC (tetrahydrocannabinol).
    Ungerleider JT; Andrysiak T
    Int J Addict; 1985 May; 20(5):691-9. PubMed ID: 2995262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy.
    Lane M; Smith FE; Sullivan RA; Plasse TF
    Am J Clin Oncol; 1990 Dec; 13(6):480-4. PubMed ID: 2173391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis.
    Orr LE; McKernan JF; Bloome B
    Arch Intern Med; 1980 Nov; 140(11):1431-3. PubMed ID: 6254456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.
    Ekert H; Waters KD; Jurk IH; Mobilia J; Loughnan P
    Med J Aust; 1979 Dec; 2(12):657-9. PubMed ID: 231736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoids in the management of severe nausea and vomiting from cancer chemotherapy. Some additional considerations.
    Garb S
    J Clin Pharmacol; 1981; 21(S1):57S-59S. PubMed ID: 6271843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nabilone: an effective antiemetic agent in patients receiving cancer chemotherapy.
    Einhorn L
    Cancer Treat Rev; 1982 Dec; 9 Suppl B():55-61. PubMed ID: 6299557
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent clinical experience with dronabinol.
    Plasse TF; Gorter RW; Krasnow SH; Lane M; Shepard KV; Wadleigh RG
    Pharmacol Biochem Behav; 1991 Nov; 40(3):695-700. PubMed ID: 1666930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy.
    McCabe M; Smith FP; Macdonald JS; Woolley PV; Goldberg D; Schein PS
    Invest New Drugs; 1988 Sep; 6(3):243-6. PubMed ID: 2847994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials with antiemetic agents in cancer patients receiving chemotherapy.
    Penta JS; Poster DS; Bruno S; Macdonald JS
    J Clin Pharmacol; 1981; 21(S1):11S-22S. PubMed ID: 6271815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy.
    Chang AE; Shiling DJ; Stillman RC; Goldberg NH; Seipp CA; Barofsky I; Rosenberg SA
    Cancer; 1981 Apr; 47(7):1746-51. PubMed ID: 6261926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dronabinol treatment of refractory nausea and vomiting related to peritoneal carcinomatosis.
    Hernandez SL; Sheyner I; Stover KT; Stewart JT
    Am J Hosp Palliat Care; 2015 Feb; 32(1):5-7. PubMed ID: 24052427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.